1-5 of 5
Dana Dibenedetti
Close
Sort by
Journal Articles

Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated Patients with Hemophilia A from the XTEND-Kids Phase 3 Clinical Trial

Lynn Malec, Manuel Carcao, Mary Mathias, Nana Kragh, Jennifer Dumont, Annemieke Willemze, Linda Bystrická, Amanda Wilson, Dana Dibenedetti
Journal: Blood
Blood (2023) 142 (Supplement 1): 507.
https://doi.org/10.1182/blood-2023-181973
Published: 2023
Journal Articles

Fitusiran Reaches People's with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)

Alok Srivastava, Savita Rangarajan, Cecil Ross, Christina Slota, Dana DiBenedetti, Viridiana Cano, Shauna Andersson, Pronabesh Dasmahapatra, José Bartelt-Hofer, Marion Afonso
Journal: Blood
Blood (2022) 140 (Supplement 1): 7989–7990.
https://doi.org/10.1182/blood-2022-166895
Published: 2022
Journal Articles

Development of a Cold Agglutinin Disease-Specific Patient-Reported Outcome Symptom Measure

Florence Joly, Pronabesh Dasmahapatra, Jun Su, Dana DiBenedetti, Katherine Kosa, Quentin Hill
Journal: Blood
Blood (2021) 138 (Supplement 1): 4057.
https://doi.org/10.1182/blood-2021-147199
Published: 2021
Journal Articles

Assessing Patient Experiences with Prophylactic Treatments for Hemophilia a: Concept Elicitation for Gene Therapy

Shawn X. Sun, Oyebimpe Olayinka-Amao, Dana DiBenedetti
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-140307
Published: 2020
Journal Articles

Patient-Reported Disease Burden: In-Depth Interviews of Patients with CAD

Jun Su, Katherine Kosa, Dana DiBenedetti
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-136788
Published: 2020